Hyundai BioScience has officially commenced a global clinical research study for its treatment candidate, Xafty (CP-COV03), aimed at tackling dengue and related diseases in Vietnam. This initiative comes amid a critical time as dengue fever, transmitted by mosquitoes, along with other mosquito-borne viruses like Zika, currently lacks a universally effective treatment approach. The company secured international clinical research approval last year and has engaged in collaborative efforts with Vietnam's National Institute of Tropical Medicine and health authorities to kickstart this vital research in Hanoi.

During the official launch event at the Lotte Hotel Convention Center in Hanoi, experts gathered to discuss the significance of this development for Southeast Asia's infectious disease response system. They heralded the trial as a pivotal point not only for the treatment of dengue but also for adopting a broader framework that could address similar viral diseases. The unique characteristics of the trial ensure that it will take place in real outbreak zones, offering an adaptable and proactive approach to fighting emerging infectious diseases.

The Vietnamese authorities, with a vision of "Vietnam to the World," regard this international trial as a major advancement in their health strategy. They express intentions to create a collaborative structure among government bodies, medical institutions, research organizations, and private enterprises to foster clinical work in actual endemic areas, thereby aiming to transform Vietnam into a key hub for infectious disease response in the Southeast Asian region. Both former Minister of Health Tran Thi Trung Chien and Deputy Minister Nguyen Chi expressed optimism that the successful execution of this global study could significantly influence public health policy and infectious disease management in the region.